"The Department of Justice's April 23, 2026 final order rescheduling FDA-approved marijuana products and qualifying state-licensed medical programs from Schedule I to Schedule III reshapes the industry's economics while leaving recreational use exactly where it is."
"Moving cannabis to Schedule III would lift the 280E burden and, just as importantly, clear a path for institutional investors who have mostly stayed away from plant-touching names because of federal illegality."
"MSOS is the clearest single-ticker way to lean into a US rescheduling story. AdvisorShares runs it as an active fund, using total return swaps to mirror the performance of US plant-touching multi-state operators."
The Department of Justice's rescheduling of FDA-approved marijuana products from Schedule I to Schedule III significantly alters the cannabis industry's economics. This change allows state medical operators to apply for DEA registration, while recreational use remains unchanged. The rescheduling lifts the burdens of Section 280E, enabling cannabis companies to deduct normal business expenses, which could attract institutional investors. Three ETFs, MSOS, CNBS, and YOLO, provide different investment strategies in response to this evolving landscape, with MSOS being highlighted as a strong option for investors.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]